321 related articles for article (PubMed ID: 20150372)
21. Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial.
Oehler C; Frei K; Rushing EJ; McSheehy PM; Weber D; Allegrini PR; Weniger D; Lütolf UM; Knuth A; Yonekawa Y; Barath K; Broggini-Tenzer A; Pruschy M; Hofer S
Oncology; 2012; 83(1):1-9. PubMed ID: 22688083
[TBL] [Abstract][Full Text] [Related]
22. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation.
Thiessen B; Stewart C; Tsao M; Kamel-Reid S; Schaiquevich P; Mason W; Easaw J; Belanger K; Forsyth P; McIntosh L; Eisenhauer E
Cancer Chemother Pharmacol; 2010 Jan; 65(2):353-61. PubMed ID: 19499221
[TBL] [Abstract][Full Text] [Related]
23. Single-agent bevacizumab is an effective treatment in recurrent glioblastoma.
Hacibekiroglu I; Kodaz H; Erdogan B; Turkmen E; Ozcelik M; Esenkaya A; Saygi HM; Uzunoglu S; Cicin I
Med Oncol; 2015 Feb; 32(2):460. PubMed ID: 25572814
[TBL] [Abstract][Full Text] [Related]
24. NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.
Peereboom DM; Ahluwalia MS; Ye X; Supko JG; Hilderbrand SL; Phuphanich S; Nabors LB; Rosenfeld MR; Mikkelsen T; Grossman SA;
Neuro Oncol; 2013 Apr; 15(4):490-6. PubMed ID: 23328813
[TBL] [Abstract][Full Text] [Related]
25. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme.
Ballman KV; Buckner JC; Brown PD; Giannini C; Flynn PJ; LaPlant BR; Jaeckle KA
Neuro Oncol; 2007 Jan; 9(1):29-38. PubMed ID: 17108063
[TBL] [Abstract][Full Text] [Related]
26. Phase I/II study of oral erlotinib for treatment of relapsed/refractory glioblastoma multiforme and anaplastic astrocytoma.
Kesavabhotla K; Schlaff CD; Shin B; Mubita L; Kaplan R; Tsiouris AJ; Pannullo SC; Christos P; Lavi E; Scheff R; Boockvar JA
J Exp Ther Oncol; 2012; 10(1):71-81. PubMed ID: 22946346
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma.
da Fonseca CO; Simão M; Lins IR; Caetano RO; Futuro D; Quirico-Santos T
J Cancer Res Clin Oncol; 2011 Feb; 137(2):287-93. PubMed ID: 20401670
[TBL] [Abstract][Full Text] [Related]
28. Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN.
Custodio A; Calles A; Pérez-Segura P
Clin Transl Oncol; 2010 Apr; 12(4):310-4. PubMed ID: 20462843
[TBL] [Abstract][Full Text] [Related]
29. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.
Brown PD; Krishnan S; Sarkaria JN; Wu W; Jaeckle KA; Uhm JH; Geoffroy FJ; Arusell R; Kitange G; Jenkins RB; Kugler JW; Morton RF; Rowland KM; Mischel P; Yong WH; Scheithauer BW; Schiff D; Giannini C; Buckner JC;
J Clin Oncol; 2008 Dec; 26(34):5603-9. PubMed ID: 18955445
[TBL] [Abstract][Full Text] [Related]
30. Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.
Reardon DA; Nabors LB; Mason WP; Perry JR; Shapiro W; Kavan P; Mathieu D; Phuphanich S; Cseh A; Fu Y; Cong J; Wind S; Eisenstat DD;
Neuro Oncol; 2015 Mar; 17(3):430-9. PubMed ID: 25140039
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.
Raymond E; Brandes AA; Dittrich C; Fumoleau P; Coudert B; Clement PM; Frenay M; Rampling R; Stupp R; Kros JM; Heinrich MC; Gorlia T; Lacombe D; van den Bent MJ;
J Clin Oncol; 2008 Oct; 26(28):4659-65. PubMed ID: 18824712
[TBL] [Abstract][Full Text] [Related]
32. Epithelial Growth Factor Receptor Inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study.
Preusser M; Gelpi E; Rottenfusser A; Dieckmann K; Widhalm G; Dietrich W; Bertalanffy A; Prayer D; Hainfellner JA; Marosi C
J Neurooncol; 2008 Sep; 89(2):211-8. PubMed ID: 18458820
[TBL] [Abstract][Full Text] [Related]
33. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.
Haas-Kogan DA; Prados MD; Tihan T; Eberhard DA; Jelluma N; Arvold ND; Baumber R; Lamborn KR; Kapadia A; Malec M; Berger MS; Stokoe D
J Natl Cancer Inst; 2005 Jun; 97(12):880-7. PubMed ID: 15956649
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme.
Puduvalli VK; Giglio P; Groves MD; Hess KR; Gilbert MR; Mahankali S; Jackson EF; Levin VA; Conrad CA; Hsu SH; Colman H; de Groot JF; Ritterhouse MG; Ictech SE; Yung WK
Neuro Oncol; 2008 Apr; 10(2):216-22. PubMed ID: 18314417
[TBL] [Abstract][Full Text] [Related]
35. Epidermal growth factor receptor serum levels and prognostic value in malignant gliomas.
Quaranta M; Divella R; Daniele A; Di Tardo S; Venneri MT; Lolli I; Troccoli G
Tumori; 2007; 93(3):275-80. PubMed ID: 17679463
[TBL] [Abstract][Full Text] [Related]
36. Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074.
Uhm JH; Ballman KV; Wu W; Giannini C; Krauss JC; Buckner JC; James CD; Scheithauer BW; Behrens RJ; Flynn PJ; Schaefer PL; Dakhill SR; Jaeckle KA
Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):347-53. PubMed ID: 20510539
[TBL] [Abstract][Full Text] [Related]
37. A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas.
Nghiemphu PL; Lai A; Green RM; Reardon DA; Cloughesy T
J Neurooncol; 2012 Nov; 110(2):245-50. PubMed ID: 22918789
[TBL] [Abstract][Full Text] [Related]
38. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
[TBL] [Abstract][Full Text] [Related]
39. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.
Raizer JJ
J Neurooncol; 2005 Aug; 74(1):77-86. PubMed ID: 16078112
[TBL] [Abstract][Full Text] [Related]
40. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.
Møller S; Grunnet K; Hansen S; Schultz H; Holmberg M; Sorensen M; Poulsen HS; Lassen U
Acta Oncol; 2012 Jul; 51(6):797-804. PubMed ID: 22548369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
